Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Notes Payables (2016)

United Therapeutics' Notes Payables history spans 8 years, with the latest figure at $900000.0 for Q2 2016.

  • On a quarterly basis, Notes Payables fell 97.21% to $900000.0 in Q2 2016 year-over-year; TTM through Jun 2016 was $900000.0, a 97.21% decrease, with the full-year FY2015 number at $5.4 million, down 95.73% from a year prior.
  • Notes Payables hit $900000.0 in Q2 2016 for United Therapeutics, down from $5.4 million in the prior quarter.
  • Over the last five years, Notes Payables for UTHR hit a ceiling of $224.7 million in Q3 2014 and a floor of $900000.0 in Q2 2016.
  • Historically, Notes Payables has averaged $104.9 million across 5 years, with a median of $90.9 million in 2014.
  • Biggest five-year swings in Notes Payables: soared 16619.21% in 2013 and later crashed 97.21% in 2016.
  • Tracing UTHR's Notes Payables over 5 years: stood at $1.3 million in 2012, then soared by 16619.21% to $215.8 million in 2013, then tumbled by 41.43% to $126.4 million in 2014, then tumbled by 95.73% to $5.4 million in 2015, then plummeted by 83.33% to $900000.0 in 2016.
  • Business Quant data shows Notes Payables for UTHR at $900000.0 in Q2 2016, $5.4 million in Q1 2016, and $5.4 million in Q4 2015.